Therapeutic options for cutaneous leishmaniasis.
BACKGROUND
Cutaneous leishmaniasis occurs worldwide in both old and new world countries with their own endemic foci. Many of those infected often experience a delay in diagnosis and inappropriate treatment.


OBJECTIVE
To review the literature in terms of the various treatment options described for cutaneous leishmaniasis.


METHODS
Literature on the treatment of cutaneous leishmaniasis retrieved by searching Index Medicus, PubMed and IndMed were reviewed.


CONCLUSIONS
Review reveals no uniform pattern or definite guidelines for its therapy. The varied and contradictory experience of different workers further confounds the clinicians involved in the care of these patients. Selection of an appropriate and customized treatment schedule is a discretion the treating clinician has to make.
Mahajan
Vikram K
VK
Department of Dermatology, Venereology & Leprosy, Indira Gandhi Medical College, Shimla, India.
Sharma
Nand Lal
NL
D000666:Amphotericin B / Q000627:therapeutic use; D000965:Antimony / Q000627:therapeutic use; D000981:Antiprotozoal Agents / Q000627:therapeutic use; D003622:Dapsone / Q000627:therapeutic use; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D016773:Leishmaniasis, Cutaneous / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy*; D012293:Rifampin / Q000627:therapeutic use
D000981:Antiprotozoal Agents; D007093:Imidazoles; D000666:Amphotericin B; D003622:Dapsone; D000965:Antimony; D012293:Rifampin